Polycythemia Vera, JAK2 V617F with Reflex to JAK2 Exon 12-15, Sequencing for Erythrocytosis, Varies
Use
This test is useful for aiding in the distinction between the myeloproliferative neoplasm polycythemia vera and other secondary erythrocytosis. The Janus kinase 2 (JAK2) V617F mutation is present in a high percentage of polycythemia vera (PV) cases, as well as some other myeloproliferative neoplasms. This test identifies the presence of this mutation to aid in the diagnosis of PV.
Special Instructions
Not provided.
Limitations
A positive result is not specific for a particular diagnosis; correlation with clinicopathologic findings and other laboratory results is necessary. A negative mutation status makes a diagnosis of polycythemia vera highly unlikely, although it does not completely exclude this possibility, other myeloproliferative neoplasms, or other neoplasms.
New York Approved
Methodology
PCR-based (qPCR)
Biomarkers
JAK2
Gene
LOINC Codes
- 31208-2 - Specimen source
- 50398-7 - Narrative diagnostic report-Imp
- 43399-5 - JAK2 p.V617F Bld/T Ql
Result Turnaround Time
7-10 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
10 mL
Minimum Volume
8 mL
Container
Lavender top (EDTA) or yellow top (ACD-B)
Collection Instructions
Invert several times to mix blood. Send whole blood specimen in original tube. Do not aliquot. Label specimen as blood.
Causes for Rejection
Gross hemolysis, Paraffin-embedded bone marrow aspirate clot or biopsy blocks, Slides, Paraffin shavings, Moderately to severely clotted
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 5 days |